Showing 6471-6480 of 9662 results for "".
SDPA: Andrew Mastro on Advancing Career By Building Yearly Goals
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-andrew-mastro-on-advancing-career-by-building-yearly-goals/29512/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Andrew Mastro, PA-C. Each year, Mastro leaves SDPA with a yearly goal in mind. He breaks down how SDPA contributes to the goal and what he does to achieve it.Pearls for Treating Atopic Skin
https://practicaldermatology.com/topics/atopic-dermatitis/pearls-for-treating-atopic-skin/29483/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, talks with dermatologist James Del Rosso, DO, about different ways to treat patients with atopic dermatitis (AD), including using a well-made moisturizers, and also exploring both the science and the use of newer topical agents. ThisASDS: Dr. Green on the Annual Meeting
https://practicaldermatology.com/conferences/asds-2024-annual-meeting/asds-dr-green-annual-meeting/29169/Lawrence Green, MD, FAAD, talks about the education and networking that make the American Society for Dermatologic Surgery Annual Meeting special.Innovations in the Aesthetic Market and Wrinkle Removal Technology
https://practicaldermatology.com/series/c-suite-chats/innovations-aesthetic-market-and-wrinkle-removal-technology/26732/Lou Scafuri, CEO of SofWave Medical, talks about what makes the company’s Synchronous Ultrasound Parallel Beam technology unique.SCALE 2024: Dr. Linda Stein Gold on What’s New and What’s Coming in AD
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-linda-stein-gold-on-whats-new-and-whats-coming-in-ad/26412/Linda Stein Gold, MD, discusses new topical, oral, and biologic drugs for the treatment of atopic dermatitis at Music City SCALE.DermwireTV: Rinvoq Approved for Pediatric Psoriatic Arthritis; J&J Acquires Novel AD Candidate
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-rinvoq-approved-for-pediatric-psoriatic-arthritis/26269/In this week's DermwireTV, the FDA approves Rinvoq for pediatric psoriatic arthritis; Johnson & Johnson acquires an AD candidate for $1.25 billion; and the president of Acclaro Medical discusses the latest FDA clearance of its Ultraclear Laser.Expanded Indications for UltraClear Cold Ablative Fractional Fiber Laser
https://practicaldermatology.com/series/c-suite-chats/expanded-indications-ultraclear-cold-ablative-fractional-fiber-laser/26268/Shlomo Assa, President and Co-Founder of Acclaro Medical, discusses the versatility of the UltraClear Cold Ablative Fractional Fiber Laser, which recently received FDA clearance to treat benign pigmented lesions and vascular dyschromia.DermwireTV: J&J Boosts Dermatology Pipeline; New Humira Biosimilar Launched
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-jj-boosts-dermatology-pipeline-new-humira-biosimilar-launched/24561/In this episode of DermwireTV, Johnson & Johnson makes a major acquisition to expand its dermatology treatment pipeline; the first high-concentration, citrate-free biosimilar to Humira is launched in the US; and in the C-Suite Chats feature, the CEO of Benev discusses the medical aesthetic markeScientifically Speaking: New Directions in Acne Management, Part 1
https://practicaldermatology.com/videos/scientifically-speaking/scientifically-speaking-new-directions-in-acne-management-part-1/19939/The recognition that inflammation is at the heart of acne has led to changes in management approaches and better understanding of how treatments work. In the first of a 2-part series, host Joel L. Cohen, MD talks to Diane Berson, MD; Linda Stein Gold, MD; and Emil Tanghetti, MD about acne approachesAlmost There: Toward Systemic Therapy for AD in Children
https://practicaldermatology.com/topics/atopic-dermatitis/almost-there-toward-systemic-therapy-for-ad-in-children/19934/With the approval of the first biologic for management of atopic dermatitis, a new era is underway, says Amy Paller, MD. She addresses the role of dupilumab in practice and provides a look ahead at other agents in the pipeline for adolescent and pediatric patients.